clioquinol has been researched along with Disease Models, Animal in 36 studies
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.
5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study investigates the anti-amnesic potential of clioquinol (5-chloro-7-iodoquinolin-8-ol) in cognitive deficits associated with experimental dementia induced by Cu-Ch." | 7.81 | Memory restorative ability of clioquinol in copper-cholesterol-induced experimental dementia in mice. ( Aggarwal, N; Mehra, R; Sodhi, RK, 2015) |
| "The present study aimed to evaluate the therapeutic potential of clioquinol (CQ), a metal chelator, on multiple sclerosis pathogenesis." | 7.79 | Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model. ( Choi, BY; Chung, TN; Jang, BG; Kim, JH; Seo, JN; Sohn, M; Suh, SW; Wu, G, 2013) |
| "Streptococcus pneumoniae is the primary cause of community-acquired bacterial pneumonia with rates of penicillin and multidrug-resistance exceeding 80% and 40%, respectively." | 5.72 | Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model. ( Bohlmann, L; Brazel, EB; Cunningham, BA; De Oliveira, DMP; Eijkelkamp, BA; El-Deeb, IM; Ganio, K; Iverson, AR; Keller, B; Maher, MJ; McDevitt, CA; McEwan, AG; Neville, SL; Rosch, JW; Sikanyika, M; Tan, A; Udagedara, SR; von Itzstein, M; Walker, MJ, 2022) |
| "Clioquinol is a metal chelator that has beneficial effects in several cellular and animal models of neurodegenerative diseases as well as on Alzheimer disease patients." | 5.35 | The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. ( Branicky, R; Carroll, M; Guimond, MP; Hayes, S; Hekimi, S; Hihi, A; McBride, K; Stepanyan, Z; Wang, Y, 2009) |
| "The present study investigates the anti-amnesic potential of clioquinol (5-chloro-7-iodoquinolin-8-ol) in cognitive deficits associated with experimental dementia induced by Cu-Ch." | 3.81 | Memory restorative ability of clioquinol in copper-cholesterol-induced experimental dementia in mice. ( Aggarwal, N; Mehra, R; Sodhi, RK, 2015) |
| "The present study aimed to evaluate the therapeutic potential of clioquinol (CQ), a metal chelator, on multiple sclerosis pathogenesis." | 3.79 | Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model. ( Choi, BY; Chung, TN; Jang, BG; Kim, JH; Seo, JN; Sohn, M; Suh, SW; Wu, G, 2013) |
| "Clioquinol acts as a zinc and copper chelator." | 2.48 | Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. ( Bareggi, SR; Cornelli, U, 2012) |
| "Clioquinol is a drug that acts on amyloid by perturbing amyloid's metallo-chemistry, and Clioquinol treatment has been shown to be beneficial in a mouse model of AD." | 2.41 | '...and C is for Clioquinol' - the AbetaCs of Alzheimer's disease. ( Melov, S, 2002) |
| "Streptococcus pneumoniae is the primary cause of community-acquired bacterial pneumonia with rates of penicillin and multidrug-resistance exceeding 80% and 40%, respectively." | 1.72 | Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model. ( Bohlmann, L; Brazel, EB; Cunningham, BA; De Oliveira, DMP; Eijkelkamp, BA; El-Deeb, IM; Ganio, K; Iverson, AR; Keller, B; Maher, MJ; McDevitt, CA; McEwan, AG; Neville, SL; Rosch, JW; Sikanyika, M; Tan, A; Udagedara, SR; von Itzstein, M; Walker, MJ, 2022) |
| "Clioquinol (CQ) has been shown to have therapeutic benefits in rodent models of neurodegenerative disorders." | 1.56 | Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway. ( Cheng, A; Huang, C; Liu, W; Luo, Q; Shi, L; Shi, R; Xia, Y; Zeng, W; Zhengli, C, 2020) |
| "Clioquinol was used in the 1950s-1970s as antimicrobial but its oral formulations were withdrawn from the market due to suspected neurotoxicity." | 1.51 | Oral clioquinol is effective in the treatment of a fly model of Candida systemic infection. ( Andrade, SF; de Araújo, BV; Fuentefria, AM; Merkel, S; Pippi, B; Staudt, KJ; Teixeira, ML; Zanette, RA, 2019) |
| "Genetic aspects of autism spectrum disorders (ASDs) have recently been extensively explored, but environmental influences that affect ASDs have received considerably less attention." | 1.42 | Trans-synaptic zinc mobilization improves social interaction in two mouse models of autism through NMDAR activation. ( Chung, C; Hsueh, YP; Huang, TN; Kim, E; Kim, K; Koh, JY; Lee, EJ; Lee, H; Shin, W, 2015) |
| " elegans model of full length Aß₁₋₄₂ expression can now be adopted for use in screens to rapidly identify and assist in development of potential therapeutics and to study underlying toxic mechanism(s) of Aß." | 1.38 | Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. ( Barnham, KJ; Bush, AI; Cherny, RA; Kenche, VB; Link, CD; Masters, CL; McColl, G; Pukala, TL; Roberts, BR; Roberts, CM; Ryan, TM, 2012) |
| "As a disease-modifying approach for Alzheimer's disease (AD), clioquinol (CQ) targets beta-amyloid (Abeta) reactions with synaptic Zn and Cu yet promotes metal uptake." | 1.35 | Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. ( Adlard, PA; Barnham, KJ; Bush, AI; Cappai, R; Charman, SA; Cherny, RA; Cortes, M; Deleva, K; Finkelstein, DI; Gautier, E; Kok, G; Laughton, K; Li, QX; Liu, X; Lynch, T; Masters, CL; Nicolazzo, JA; Perez, K; Ritchie, CW; Robb, E; Smith, JP; Tanzi, RE; Volitakis, I; Wilkins, S, 2008) |
| "Clioquinol is a metal chelator that has beneficial effects in several cellular and animal models of neurodegenerative diseases as well as on Alzheimer disease patients." | 1.35 | The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. ( Branicky, R; Carroll, M; Guimond, MP; Hayes, S; Hekimi, S; Hihi, A; McBride, K; Stepanyan, Z; Wang, Y, 2009) |
| "Clioquinol (CQ) is a "metal protein attenuating compound" that crosses the blood-brain barrier and binds, with high affinity, copper(II) and zinc(II), two metal ions critically involved in amyloid-beta aggregation and toxicity." | 1.35 | Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. ( Casamenti, F; Casini, A; Fiorentini, A; Francese, S; Gabbiani, C; Grossi, C; Luccarini, I; Messori, L; Moneti, G; Rosi, MC, 2009) |
| "Clioquinol treatment of transgenic Huntington's mice (R6/2) improved behavioral and pathologic phenotypes, including decreased huntingtin aggregate accumulation, decreased striatal atrophy, improved rotarod performance, reduction of weight loss, normalization of blood glucose and insulin levels, and extension of lifespan." | 1.33 | Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. ( Hamby, A; Massa, SM; Nguyen, T, 2005) |
| "8 g/kg) in shorter periods (19-47 days) and there was no difference between each group on the increasing dosage and on fixed dosage." | 1.25 | Neurotoxity of iodoxyquinoline: a further study on beagle dogs. ( Ikeda, H; Kuroda, S; Otsuki, S; Tateishi, J, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (33.33) | 29.6817 |
| 2010's | 15 (41.67) | 24.3611 |
| 2020's | 6 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Brazel, EB | 1 |
| Tan, A | 1 |
| Neville, SL | 1 |
| Iverson, AR | 1 |
| Udagedara, SR | 1 |
| Cunningham, BA | 1 |
| Sikanyika, M | 1 |
| De Oliveira, DMP | 1 |
| Keller, B | 1 |
| Bohlmann, L | 1 |
| El-Deeb, IM | 1 |
| Ganio, K | 1 |
| Eijkelkamp, BA | 1 |
| McEwan, AG | 1 |
| von Itzstein, M | 1 |
| Maher, MJ | 1 |
| Walker, MJ | 1 |
| Rosch, JW | 1 |
| McDevitt, CA | 1 |
| Wang, Z | 1 |
| Cao, M | 2 |
| Xiang, H | 1 |
| Wang, W | 1 |
| Feng, X | 1 |
| Yang, X | 1 |
| Shi, L | 1 |
| Huang, C | 1 |
| Luo, Q | 1 |
| Xia, Y | 1 |
| Liu, W | 1 |
| Zeng, W | 1 |
| Cheng, A | 1 |
| Shi, R | 1 |
| Zhengli, C | 1 |
| Pretsch, D | 1 |
| Rollinger, JM | 1 |
| Schmid, A | 1 |
| Genov, M | 1 |
| Wöhrer, T | 1 |
| Krenn, L | 1 |
| Moloney, M | 1 |
| Kasture, A | 1 |
| Hummel, T | 1 |
| Pretsch, A | 1 |
| da Costa, B | 1 |
| Pippi, B | 2 |
| Berlitz, SJ | 1 |
| Carvalho, AR | 1 |
| Teixeira, ML | 2 |
| Külkamp-Guerreiro, IC | 1 |
| Andrade, SF | 2 |
| Fuentefria, AM | 2 |
| Zhu, Y | 1 |
| Chang, J | 1 |
| Tan, K | 1 |
| Huang, SK | 1 |
| Liu, X | 2 |
| Wang, X | 1 |
| Zhang, H | 1 |
| Li, S | 1 |
| Duan, X | 1 |
| Chang, Y | 1 |
| Fan, Y | 1 |
| Cao, P | 1 |
| Merkel, S | 1 |
| Staudt, KJ | 1 |
| de Araújo, BV | 1 |
| Zanette, RA | 1 |
| Zhang, YH | 1 |
| Raymick, J | 1 |
| Sarkar, S | 1 |
| Lahiri, DK | 1 |
| Ray, B | 1 |
| Holtzman, D | 1 |
| Dumas, M | 1 |
| Schmued, LC | 1 |
| Geiser, J | 1 |
| De Lisle, RC | 1 |
| Finkelstein, D | 1 |
| Adlard, PA | 7 |
| Bush, AI | 8 |
| Andrews, GK | 1 |
| Parncutt, J | 1 |
| Lal, V | 1 |
| James, S | 1 |
| Hare, D | 1 |
| Doble, P | 1 |
| Finkelstein, DI | 6 |
| Lei, P | 1 |
| Ayton, S | 1 |
| Appukuttan, AT | 1 |
| Volitakis, I | 3 |
| Mehra, R | 1 |
| Sodhi, RK | 1 |
| Aggarwal, N | 1 |
| Lee, EJ | 1 |
| Lee, H | 1 |
| Huang, TN | 1 |
| Chung, C | 1 |
| Shin, W | 1 |
| Kim, K | 1 |
| Koh, JY | 1 |
| Hsueh, YP | 1 |
| Kim, E | 1 |
| Hare, DJ | 2 |
| Billings, JL | 2 |
| Sedjahtera, A | 1 |
| Nurjono, M | 3 |
| Arthofer, E | 1 |
| George, S | 1 |
| Culvenor, JG | 1 |
| Cherny, RA | 3 |
| Gautier, E | 1 |
| Robb, E | 1 |
| Cortes, M | 1 |
| Smith, JP | 1 |
| Perez, K | 1 |
| Laughton, K | 1 |
| Li, QX | 1 |
| Charman, SA | 1 |
| Nicolazzo, JA | 1 |
| Wilkins, S | 1 |
| Deleva, K | 1 |
| Lynch, T | 1 |
| Kok, G | 1 |
| Ritchie, CW | 1 |
| Tanzi, RE | 1 |
| Cappai, R | 2 |
| Masters, CL | 2 |
| Barnham, KJ | 2 |
| Wang, Y | 1 |
| Branicky, R | 1 |
| Stepanyan, Z | 1 |
| Carroll, M | 1 |
| Guimond, MP | 1 |
| Hihi, A | 1 |
| Hayes, S | 1 |
| McBride, K | 1 |
| Hekimi, S | 1 |
| Grossi, C | 1 |
| Francese, S | 1 |
| Casini, A | 1 |
| Rosi, MC | 1 |
| Luccarini, I | 1 |
| Fiorentini, A | 1 |
| Gabbiani, C | 1 |
| Messori, L | 1 |
| Moneti, G | 1 |
| Casamenti, F | 1 |
| Rival, T | 1 |
| Page, RM | 1 |
| Chandraratna, DS | 1 |
| Sendall, TJ | 1 |
| Ryder, E | 1 |
| Liu, B | 1 |
| Lewis, H | 1 |
| Rosahl, T | 1 |
| Hider, R | 1 |
| Camargo, LM | 1 |
| Shearman, MS | 1 |
| Crowther, DC | 1 |
| Lomas, DA | 1 |
| Bareggi, SR | 1 |
| Cornelli, U | 1 |
| Bica, L | 1 |
| White, AR | 2 |
| Filiz, G | 2 |
| Crouch, PJ | 2 |
| Donnelly, PS | 1 |
| Wang, T | 1 |
| Wang, CY | 1 |
| Shan, ZY | 1 |
| Teng, WP | 1 |
| Wang, ZY | 1 |
| McColl, G | 1 |
| Roberts, BR | 1 |
| Pukala, TL | 1 |
| Kenche, VB | 1 |
| Roberts, CM | 1 |
| Link, CD | 1 |
| Ryan, TM | 1 |
| Choi, BY | 1 |
| Jang, BG | 1 |
| Kim, JH | 1 |
| Seo, JN | 1 |
| Wu, G | 1 |
| Sohn, M | 1 |
| Chung, TN | 1 |
| Suh, SW | 1 |
| Ponti, W | 2 |
| Sala, M | 1 |
| Pollera, C | 2 |
| Braida, D | 1 |
| Poli, G | 2 |
| Bareggi, S | 2 |
| Nguyen, T | 1 |
| Hamby, A | 1 |
| Massa, SM | 1 |
| Lucchini, B | 1 |
| Formentin, E | 1 |
| Masuda, T | 1 |
| Hida, H | 1 |
| Kanda, Y | 1 |
| Aihara, N | 1 |
| Ohta, K | 1 |
| Yamada, K | 1 |
| Nishino, H | 1 |
| Chen, WH | 1 |
| Wang, M | 1 |
| Yu, SS | 1 |
| Su, L | 1 |
| Zhu, DM | 1 |
| She, JQ | 1 |
| Cao, XJ | 1 |
| Ruan, DY | 1 |
| Price, KA | 1 |
| Caragounis, A | 1 |
| Du, T | 1 |
| Thomas, PK | 1 |
| Schaumburg, HH | 1 |
| Spencer, PS | 1 |
| Kaeser, HE | 1 |
| Pallis, CA | 1 |
| Rose, FC | 1 |
| Wadia, NH | 1 |
| Tateishi, J | 3 |
| Melov, S | 1 |
| Kuroda, S | 2 |
| Ikeda, H | 1 |
| Otsuki, S | 2 |
| Saito, A | 1 |
4 reviews available for clioquinol and Disease Models, Animal
| Article | Year |
|---|---|
Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders.
Topics: Animals; Clinical Trials as Topic; Clioquinol; Disease Models, Animal; Humans; Neurodegenerative Dis | 2012 |
The role of metals in modulating metalloprotease activity in the AD brain.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Brain; Cell Culture Techniques; Chelatin | 2008 |
Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals.
Topics: Animals; Brain Injuries; Clioquinol; Diagnosis, Differential; Disease Models, Animal; Humans; Japan; | 2000 |
'...and C is for Clioquinol' - the AbetaCs of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Chelating Agents; Clioquinol; Disease Models, Ani | 2002 |
32 other studies available for clioquinol and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model.
Topics: Ampicillin; Ampicillin Resistance; Animals; Anti-Bacterial Agents; Clioquinol; Disease Models, Anima | 2022 |
WBQ5187, a Multitarget Directed Agent, Ameliorates Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease and Modulates Cerebral β-Amyloid, Gliosis, cAMP Levels, and Neurodegeneration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anesthetics, General; Animals; Benzofurans; Biological Ava | 2019 |
Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson's disease through AKT/mTOR pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Clioquinol; Disease Models, Animal; Haplorhin | 2020 |
Prolongation of metallothionein induction combats Aß and α-synuclein toxicity in aged transgenic Caenorhabditis elegans.
Topics: Aging; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modi | 2020 |
Evaluation of activity and toxicity of combining clioquinol with ciclopirox and terbinafine in alternative models of dermatophytosis.
Topics: Animals; Antifungal Agents; Ciclopirox; Clioquinol; Dermatomycoses; Disease Models, Animal; Drug Com | 2021 |
Clioquinol Attenuates Pulmonary Fibrosis through Inactivation of Fibroblasts via Iron Chelation.
Topics: Animals; Bleomycin; Chelating Agents; Clioquinol; Disease Models, Animal; Female; Fibroblasts; Human | 2021 |
Oral clioquinol is effective in the treatment of a fly model of Candida systemic infection.
Topics: Administration, Oral; Animals; Antifungal Agents; Candidiasis; Chick Embryo; Chickens; Clioquinol; D | 2019 |
Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antigens, CD; Ant | 2013 |
Clioquinol synergistically augments rescue by zinc supplementation in a mouse model of acrodermatitis enteropathica.
Topics: Acrodermatitis; Animals; Cation Transport Proteins; Clioquinol; Dietary Supplements; Disease Models, | 2013 |
Metal chaperones prevent zinc-mediated cognitive decline.
Topics: Analysis of Variance; Animals; Carrier Proteins; Cation Transport Proteins; Clioquinol; Cognition Di | 2015 |
Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Clioquinol; Dementia; Disease Models, Animal; Dopami | 2015 |
Memory restorative ability of clioquinol in copper-cholesterol-induced experimental dementia in mice.
Topics: Acetylcholinesterase; Animals; Anticholesteremic Agents; Antioxidants; Behavior, Animal; Biomarkers; | 2015 |
Trans-synaptic zinc mobilization improves social interaction in two mouse models of autism through NMDAR activation.
Topics: Amygdala; Animals; Autistic Disorder; Behavior, Animal; Chelating Agents; Clioquinol; Crosses, Genet | 2015 |
Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice.
Topics: alpha-Synuclein; Animals; Brain; Clioquinol; Cognition Disorders; Disease Models, Animal; Explorator | 2016 |
Effects of Neonatal Iron Feeding and Chronic Clioquinol Administration on the Parkinsonian Human A53T Transgenic Mouse.
Topics: Animals; Animals, Newborn; Clioquinol; Disease Models, Animal; Humans; Iron; Iron Chelating Agents; | 2016 |
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim | 2008 |
The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1.
Topics: Aging; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Chelating Agents; Clioquino | 2009 |
Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim | 2009 |
Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Apoferritins; Brai | 2009 |
Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cells, Cultured; Clioquinol; Dendritic Spines; Disease Models, Animal; F | 2011 |
Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AβPP/PS1 transgenic mouse brain.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Chelating | 2012 |
Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Caenorhabditis ele | 2012 |
Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model.
Topics: Animals; Axons; Behavior, Animal; Blotting, Western; Chelating Agents; Clioquinol; Copper; Disease M | 2013 |
In vivo model for the evaluation of molecules active towards transmissible spongiform encephalopathies.
Topics: Animals; Anti-Infective Agents; Avoidance Learning; Clioquinol; Cricetinae; Disease Models, Animal; | 2004 |
Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.
Topics: Animals; Behavior, Animal; Blood Glucose; Body Weight; Cell Death; Cell Line; Clioquinol; Disease Mo | 2005 |
Evaluation of anti-prionic activity of clioquinol in an in vivo model (Mesocricetus auratus).
Topics: Animals; Anti-Infective Agents; Brain Diseases; Central Nervous System; Clioquinol; Cricetinae; Dise | 2005 |
Oral administration of metal chelator ameliorates motor dysfunction after a small hemorrhage near the internal capsule in rat.
Topics: Administration, Oral; Analysis of Variance; Animals; Behavior, Animal; Cell Count; Cells, Cultured; | 2007 |
Clioquinol and vitamin B12 (cobalamin) synergistically rescue the lead-induced impairments of synaptic plasticity in hippocampal dentate gyrus area of the anesthetized rats in vivo.
Topics: Analysis of Variance; Anesthesia; Animals; Clioquinol; Dentate Gyrus; Disease Models, Animal; Dose-R | 2007 |
Central distal axonopathy syndromes: newly recognized models of naturally occurring human degenerative disease.
Topics: Animals; Axons; Central Nervous System Diseases; Clioquinol; Disease Models, Animal; Dogs; Humans; L | 1984 |
Neurotoxity of iodoxyquinoline: a further study on beagle dogs.
Topics: Administration, Oral; Animals; Clioquinol; Disease Models, Animal; Dogs; Intestines; Kidney; Liver; | 1975 |
Myelo-optic neuropathy induced by clioquinol in animals.
Topics: Animals; Cats; Clioquinol; Disease Models, Animal; Dogs; Hydroxyquinolines; Macaca; Optic Neuritis; | 1971 |